13th International Congress on Infectious Diseases Abstracts, Poster Presentations study, was to test for antibacterial activity of a green alga, Caulerpa sertularioides from the Persian Gulf.
Background: Beta-lactam antibiotics efficacy depends on the duration of time in which serum concentration exceeds MIC. The aim of open prospective randomized study was to compare clinical and microbiolgical efficacy of continuous infusion versus intermittent administration of meropenem in critically ill patients.
Methods: Patients admitted to interdisciplinary ICU suffering from severe infection indicated to meropenem administration were randomized to receive either a 2 g iv loading dose of meropenem followed by a daily 4 g continuous infusion (CONTINUOUS group) or intermittent administration of 2 g of meropenem iv in every 8 h (INTERMITTENT group). Antibiotic therapy was stopped at improvement of clinical state and signs of subsidence of infection (body temperature below 38,3
• C, white blood count <10000/mm3 or decrease below 25% of maximal value, C-reactive protein -CRP ≤100 mg/l). Microbiological efficacy was evaluated as success (eradication or presumed eradication) or failure (persistence or rezistence development). The age, gender, APACHE II score, SOFA score, length of ICU stay, length of mechanical ventilation, type of infection were assessed. Success, failure and length of meropenem therapy and total dose of meropenem were evaluated. Mann-Whitney, unpaired t-test and Chi-squared test were used accordingly; p < 0,05 was considered statistically significant.
Results: A total of 84 patients (55 men and 29 women) were enrolled and randomized in CONTINUOUS (n = 42) and INTERMITTENT (n = 44) group. No significant differences between CONTINUOUS and INTERMITTENT group in assessed parameters were found except for total dose of meropenem.
Conclusion Background: In 2005, tigecycline (TIG) a novel glycylcycline was approved in the US for treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI). As such, it is important to continue to monitor TIG activity against target pathogens for these indications. This study reports the in vitro activity of TIG against Enterobacteriaceae (EN) and Acinetobacter spp. (AC) as observed during development ('01-'04), and during the years following its approval for use ('05, '06 and '07). The results were further stratified to determine whether any potential variability in TIG activity against EN and AC exists according to patient location (PL) and specimen source (SS).
Methods Results: Against EN overall, TIG had an MIC 90 of 1 mg/L in each study period ('01-'04, '05, '06, and '07), and EN isolates were ≥99% susceptible (S) to TIG throughout. The activity of TIG for each study period was consistent by MIC 90 , regardless of PL (MIC 90 = 1 mg/L against OP, ICU, and IP) or SS (MIC 90 = 1 mg/L against BL, RP, and SST, 0.5-1 mg/L for UR isolates). In the most recent period evaluated ('07), EN isolates were ≥99% S to TIG for all PL and SS evaluated. Against AC overall, TIG had an MIC 90 of 2 mg/L in '01-'04 and '07 and 1 mg/L in '05 and '06. The % S of AC went from 97% in '01-'04 to ≥99.5% in '05, '06 and '07. For each study period, little variation in TIG MIC 90 was observed either by PL or SS (1-2 mg/L). In '07, 100% of tested acinetobacter were susceptible to TIG (EN BPs were utilized for AC).
Conclusion: Little to no alteration in the in vitro activity of TIG against EN and AC was apparent by MIC 90 Methods: Eighteen sites in France, Germany, Spain, Italy and UK utilized standardized, reference-quality agar diffusion methods including Etest and CLSI (M2-A9) disk diffusion (DD) tests with concurrent QC (CLSI M100-S18, 2008). 1,127 strains were tested against dalbavancin and comparison glycopeptides by Etest. DD was used for linezolid, cefoxitin, levofloxacin, gentamicin, tetracycline, erythromycin, clindamycin (plus D-test), penicillin and ceftriaxone. Dalbavancin susceptibility was defined at ≤0.25 mg/L.
Results: Dalbavancin exhibited potent activity against the SA and coagulase-negative staphylococci (CoNS; MIC 50/90 , 0.064/0.19 mg/L), and BHS (MIC 50/90 , ≤0.016/0.047 mg/L). Overall, vancomycin and teicoplanin were ≥eight-fold less potent. Italy had higher dalbavancin MIC values (two-fold) for SA and the highest MRSA rate (44%) compared to other nations (8-36%). Dalbavancin MIC 90 values were slightly higher for group B (0.047 mg/L) compared to group A (0.032 mg/L) streptococci. Nearly 4% of BHS isolates were levofloxacin-non-susceptible. Among SA, resistance rates were: erythromycin (29%), clindamycin (13%), gentamicin (10%), and levofloxacin (29%) with higher resistance rates among MRSA. Inducible clindamycin resistance was high among SA (72%) and CoNS (48%) and less among BHS (25%). Rare strains had non-susceptible MIC values for linezolid (0.3%) and vancomycin (0.1%)
Conclusions: Dalbavancin demonstrated pronounced activity (MIC, ≤0.25 mg/L) against staphylococci and BHS from European countries. Due to dalbavancin's high molecular weight, like other peptides, care must be taken when interpreting Etest-generated MICs (false resistance). Dalbavancin provides coverage of contemporary Grampositive pathogens, including resistant isolates recovered from patients in Europe, confirming earlier USA reports. Background: Ertapenem is a relatively new carbapenem with broad activity. There are however limited studies regarding its efficacy in bacteremic patients. We evaluated the in-vitro activity of Ertapenem against blood culture isolates (community onset and nosocomial) at a tertiary hospital.
Methods: Bacteria isolated from blood cultures from hospitalized patients admitted to the National University Hospital, Singapore (Dec 2003 -May 2004 were identified using the Vitek instrument (bioMerieux, NC) and Microbact 12A and 12B (Oxoid Australia). Gram-stain, catalase, coagulase (Pastorex Staph Plus, Bio-Rad, CA) and PYR disk testing were done for Staphylococcusand Streptococcus spp. Ertapenem susceptibilities were determined using the KirbyBauer disk method on cation-adjusted Mueller-Hinton plates according to the CLSI performance standards. Burkholderia pseudomallei (B. pseudomallei) isolates were further tested using the E-test (AB Biodisk, Sweden).
Results: 333 blood stream isolates were studied, including 157 Enterobacteraciae (73 Extended spectrum beta-lactamase (ESBL) positive) and 29 isolates of B. pseudomallei. All 157 Enterobacteraciae isolates were Ertapenem susceptible. 26 B. pseudomallei strains were susceptible and 3 strains intermediate to Ertapenem by disk testing, but the E-test showed that only 5 of the 29 strains were susceptible (MIC≤2 mcg/ml). Of the non-fermenting gramnegatives, 26 of 64 isolates were susceptible (including 4/6 B. cepacia, 8/26 A. baumanii and 3/10 P. aeruginosa isolates). All isolates of S. maltophila (9/9) were resistant. Of the gram-positives, 2/2 L. monocytogenes and all S. viridans (5/5), beta-hemolytic Streptococci (11/11), S. pneumoniae (6/6), methicillin susceptible S. aureus (32/32) were susceptible. All 12 strains of penicillin susceptible E. faecalis were non-susceptible to Ertapenem, whilst 9 of the 10 B. fragilis strains tested were
Conclusions: Ertapenem demonstrates excellent activity against enterobacteraciae including ESBL producing strains at our institution but is lacking against A. baumannii, P. aeruginosa, S. maltophilia and E. faecalis. It also has poor activity against B. pseudomallei and cannot be recommended as therapy for melioidosis. doi:10.1016/j.ijid.2008.05.1067 
